Study guide
Heart Failure (HFrEF & HFpEF) Diagnosis, Staging & 4-Pillar GDMT
AANPCB Adult-Gerontology Primary Care Nurse Practitioner A-GNP
Track your progress as you read
Finished sections get a check mark.
1 Exam Structure, APRN Foundations & Geriatric Assessment
A-GNP Exam Logistics, Blueprint & Scoring Structure APRN Scope of Practice, Consensus Model & Interprofessional Collaboration Comprehensive Health History & Subjective Assessment Across Adult Lifespan Comprehensive Physical Examination & Clinical Assessment Skills
2 Health Assessment, Diagnostic Reasoning & Clinical Procedures
Diagnostic Reasoning, Test Interpretation & Clinical Decision-Making Screening Guidelines & Evidence-Based Health Promotion (USPSTF) Comprehensive Geriatric Assessment (CGA), Frailty & Function In-Office Clinical Procedures, ECG Interpretation & Minor Surgical Skills
3 Cardiovascular & Peripheral Vascular Disorders
Essential Hypertension & Hypertensive Urgency/Emergency Management Coronary Artery Disease, Acute Coronary Syndromes & Post-MI Care Heart Failure (HFrEF & HFpEF) Diagnosis, Staging & 4-Pillar GDMT Arrhythmias (Atrial Fibrillation), Valvular Heart Disease & PAD
4 Respiratory, HEENT & Dermatological Disorders
Asthma Management across the Adult Lifespan (GINA Guidelines) Chronic Obstructive Pulmonary Disease (COPD) Staging & Management (GOLD Guidelines) Community-Acquired Pneumonia & Lower Respiratory Tract Infections Common HEENT Disorders: Otitis, Sinusitis, Pharyngitis, Glaucoma & Macular Degeneration
5 Endocrine, Metabolic & Renal/Genitourinary Disorders
Type 2 Diabetes Mellitus Management Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Subclinical Disease Chronic Kidney Disease (CKD) Staging & Diabetic/Hypertensive Nephropathy Genitourinary Disorders: BPH, Urinary Incontinence, UTIs & Prostatitis
6 Gastrointestinal, Hematologic & Immunologic Disorders
Upper Gastrointestinal Disorders: Dyspepsia, GERD, PUD & H. pylori Lower Gastrointestinal Disorders: IBS, IBD, Diverticulitis & Colorectal Screening Liver, Biliary & Pancreatic Disorders: NAFLD/MASLD, Cirrhosis & Cholecystitis Hematologic & Immunologic Disorders: Anemias, Anticoagulation & Immunizations
7 Neurological, Cognitive & Psychiatric Disorders
Cognitive Assessment: Delirium, Dementia & Mild Cognitive Impairment Neurological Disorders: Stroke, TIA, Parkinson's Disease & Headache Syndromes Major Depressive Disorder & Anxiety Disorders in Adults & Older Adults Sleep Disorders, Insomnia & Restless Legs Syndrome
8 Geriatric Syndromes, Polypharmacy & Deprescribing
The Beers Criteria & STOPP/START Criteria for Potentially Inappropriate Medication Use Polypharmacy Management, Pharmacokinetics/Pharmacodynamics in Aging & Deprescribing Protocols Fall Risk Assessment (CDC STEADI), Gait/Balance & Mobility Impairments Pressure Injury Prevention/Staging, Urinary/Fecal Incontinence & Frailty Assessment
9 APRN Professional Practice, Ethics, Quality & Healthcare Policy
Musculoskeletal Disorders: Osteoarthritis, Osteoporosis, Gout & Back Pain Dermatological Disorders: Lesions, Skin Cancers, Infections & Rash Evaluation Palliative Care, Advance Care Planning, Pain Management & End-of-Life APRN Professional Practice, Quality Improvement, Ethics & Healthcare Policy
Heart Failure (HFrEF & HFpEF) Diagnosis, Staging & 4-Pillar GDMT
Key Takeaways Explain This Topic AI
Heart failure is classified by ejection fraction into HFrEF (LVEF <=40%), HFmrEF (LVEF 41-49%), and HFpEF (LVEF >=50%).
The 4-pillar Guideline-Directed Medical Therapy (GDMT) for HFrEF consists of an ARNI (sacubitril/valsartan preferred), an evidence-based beta-blocker (carvedilol, metoprolol succinate, bisoprolol), an MRA (spironolactone or eplerenone), and an SGLT2 inhibitor (dapagliflozin or empagliflozin).
A mandatory 36-hour washout period is required when transitioning a patient from an ACE inhibitor to an ARNI (sacubitril/valsartan) to prevent severe angioedema.
SGLT2 inhibitors (empagliflozin and dapagliflozin) are recommended across the entire spectrum of ejection fraction, providing proven mortality and hospitalization reductions in both HFrEF and HFpEF.
Digoxin has a narrow therapeutic range (0.5-0.9 ng/mL) and does not reduce overall mortality in heart failure; toxicity manifests with visual disturbances (yellow-green halos/xanthopsia), nausea, vomiting, confusion, and heart block.
Last updated: July 2026
- Heart Failure (HFrEF & HFpEF) Diagnosis, Staging & 4-Pillar GDMT
- Classification, Pathophysiology, and Neurohormonal Activation
Heart failure (HF) is classified by Left Ventricular Ejection Fraction (LVEF) on echocardiography:
Heart Failure with Reduced Ejection Fraction (HFrEF): LVEF <=40% . Impaired contractility (systolic dysfunction) primarily caused by ischemic heart disease or dilated cardiomyopathy.
Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF): LVEF 41% to 49% . Managed similarly to HFrEF.
Heart Failure with Preserved Ejection Fraction (HFpEF): LVEF >=50% . Impaired relaxation and diastolic stiffness (diastolic dysfunction) associated with aging, hypertension, obesity, metabolic syndrome, and AFib.
Progression of HFrEF is driven by chronic neurohormonal activation:
RAAS Activation: Reduced renal perfusion stimulates renin release, raising angiotensin II and aldosterone. This causes arterial vasoconstriction, sodium/water retention, myocardial fibrosis, and LV remodeling.
Sympathetic Overdrive: Elevated norepinephrine causes tachycardia, increased oxygen demand, cardiotoxicity, and beta-1 receptor downregulation.
Natriuretic Peptide Breakdown: Endogenous counter-regulatory mechanisms (ANP and BNP) are overwhelmed by sustained neurohormonal stress.
Diagnostic Workup: Clinical Signs, Biomarkers, and Imaging
Diagnosis synthesizes clinical history, exam findings, biomarkers, and imaging.
Framingham Criteria: Requires 2 major criteria OR 1 major + 2 minor criteria:
Major Criteria: Paroxysmal nocturnal dyspnea, orthopnea, jugular venous distension (JVD >4 cm), rales, cardiomegaly, acute pulmonary edema, S3 gallop, hepatojugular reflux, weight loss >4.5 kg in 5 days on diuretics.
Minor Criteria: Ankle edema, nocturnal cough, exertional dyspnea, hepatomegaly, pleural effusion, tachycardia (HR >120 bpm).
Biomarkers: B-type Natriuretic Peptide (BNP >100 pg/mL) or NT-proBNP (>300 pg/mL) supports acute heart failure. Normal levels rule out HF.
Clinical Pearls: Obesity lowers natriuretic peptide levels. Aging and CKD elevate levels. Patients taking an ARNI (sacubitril/valsartan) display elevated plasma BNP because sacubitril inhibits neprilysin (which degrades BNP). Therefore, NT-proBNP MUST be measured instead of BNP to evaluate patients on an ARNI.
Echocardiography: Transthoracic Echocardiography (TTE) is mandatory to quantify LVEF, chamber size, wall motion, and diastolic filling pressures (E/e' ratio).
ACC/AHA Staging System vs. NYHA Functional Classification
Stage A: At risk without structural heart disease (HTN, DM).
Stage B: Structural heart disease without HF symptoms (low EF, prior MI).
Stage C: Structural heart disease with prior or current HF symptoms.
Stage D: Refractory HF requiring advanced interventions.
NYHA Class I: No limitation of physical activity.
NYHA Class II: Slight limitation; comfortable at rest, ordinary activity causes symptoms.
NYHA Class III: Marked limitation; comfortable at rest, less than ordinary activity causes symptoms.
NYHA Class IV: Symptoms present at rest; unable to carry on any physical activity.
Recognizing that NYHA functional class fluctuates based on symptom control and treatment response whereas ACC/AHA staging only progresses forward is essential for clinical tracking.
The 4-Pillar Guideline-Directed Medical Therapy (GDMT) for HFrEF
All HFrEF patients (LVEF <=40%) should receive 4-Pillar GDMT :
GDMT Pillar Class Preferred Recommended Agents Key Prescribing Rules & Monitoring Parameters
Pillar 1: ARNI ; (or ACEi / ARB) Sacubitril / Valsartan (ARNI) ; (Initial 24/26 mg or 49/51 mg BID; target 97/103 mg BID) • Preferred over ACEi/ARB for mortality reduction.; • MANDATORY RULE: Enforce a 36-hour washout period when switching from an ACEi to ARNI to prevent severe angioedema.; • Monitor K+ and creatinine.
Pillar 2: Beta-Blockers Carvedilol , Metoprolol Succinate XL , or Bisoprolol • ONLY these 3 agents reduce mortality in HFrEF.; • Titrate slowly. Avoid in acutely decompensated HF.
Pillar 3: MRA Spironolactone (12.5-25 mg) or Eplerenone (25-50 mg) • Indicated for NYHA Class II-IV with LVEF <=40%.; • Requires K+ <5.0 mEq/L and eGFR >30 mL/min/1.73 m² .
Pillar 4: SGLT2 Inhibitors Dapagliflozin (10 mg) or Empagliflozin (10 mg) • Class I recommendation for ALL HFrEF patients regardless of diabetes status.; • Reduces HF hospitalization and CV death.
Management of HFpEF (LVEF >=50%)
SGLT2 inhibitors (Dapagliflozin 10 mg or Empagliflozin 10 mg) are a Class I recommendation for HFpEF (EMPEROR-Preserved, DELIVER), significantly reducing HF hospitalizations and CV death.
Additional options in HFpEF include MRAs (spironolactone), ARNI (sacubitril/valsartan), and loop diuretics for fluid overload, combined with strict blood pressure control (<130/80 mmHg).
Symptom Control and Device Therapy
Loop Diuretics (Furosemide, Bumetanide, Torsemide): Control congestion and restore euvolemia. Diuretics improve symptoms but do NOT reduce overall mortality .
Device Therapy: Implantable Cardioverter-Defibrillator (ICD) is recommended for primary prevention of sudden cardiac death if LVEF <=35% despite >=3 months of optimal GDMT. Cardiac Resynchronization Therapy (CRT) is indicated for LVEF <=35%, LBBB, and QRS >=150 ms.
Geriatric Considerations & Digoxin Toxicity
Digoxin Clinical Rules: Digoxin may be added for symptomatic control in persistent NYHA Class III-IV HFrEF or AFib rate control. Digoxin does NOT reduce mortality . Therapeutic concentration window is narrow ( 0.5 to 0.9 ng/mL ).
Digoxin Toxicity Symptoms: Anorexia, nausea, vomiting, confusion, and visual disturbances ( xanthopsia —yellow-green halos around lights). Cardiac manifestations include sinus bradycardia and AV block.
Toxicity Triggers: Hypokalemia (potassium competes with digoxin for Na+/K+-ATPase binding; low potassium enhances digoxin binding and toxicity), hypomagnesemia, and renal decline.
Patient Education: Educate on daily morning weight checks after voiding. Patients must report weight gain of >2 to 3 lbs in 24 hours or >5 lbs in 1 week , indicating fluid retention requiring loop diuretic adjustment. Restrict sodium to <2,000 mg/day.